유럽 연합 - 영어 - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - diabetes mellitus - drugs used in diabetes - treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindications;in addition to other medicinal products for the treatment of diabetes.for study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

말레이시아 - 영어 - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novo nordisk pharma (malaysia) sdn. bhd. - liraglutide; insulin degludec -

유럽 연합 - 영어 - EMA (European Medicines Agency)

novo nordisk a/s - liraglutide - diabetes mellitus, type 2 - drugs used in diabetes - victoza is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.for study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

novo nordisk pharmaceuticals ltd - liraglutide 6 mg/ml;   - solution for injection - 6 mg/ml - active: liraglutide 6 mg/ml   excipient: dibasic sodium phosphate dihydrate hydrochloric acid phenol propylene glycol sodium hydroxide water for injection - glycaemic control victoza is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus.

유럽 연합 - 영어 - EMA (European Medicines Agency)

novo nordisk a/s - liraglutide - obesity; overweight - drugs used in diabetes - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of• ≥ 30 kg/m² (obese), or• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.

인도 - 영어 - Central Drugs Standard Control Organization

novo nordisk - liraglutide glucagon like peptide-1, analougue (glp-1 analogue) (biosynthetic r-dna origin) victoza - 6mg/ml - 3ml

캐나다 - 영어 - Health Canada

glaxosmithkline inc - albiglutide - powder for solution - 30mg - albiglutide 30mg - miscellaneous antidiabetic agents

캐나다 - 영어 - Health Canada

glaxosmithkline inc - albiglutide - powder for solution - 50mg - albiglutide 50mg - miscellaneous antidiabetic agents

캐나다 - 영어 - Health Canada

novo nordisk canada inc - semaglutide - tablet - 3mg - semaglutide 3mg - incretin mimetics

캐나다 - 영어 - Health Canada

novo nordisk canada inc - semaglutide - tablet - 7mg - semaglutide 7mg - incretin mimetics